Cefoperazone/Sulbactam is more efficient in the treatment of uraemic patients with pulmonary infection compared with cefoperazone, which does not increase adverse reactions and is well tolerated2
Resistance Rates of Common* Gram-negative Bacteria in AECOPD Lower RTIs (%)2
Adapted from Hu F, et al. 2016.
*Comparison between cefoperazone/sulbactam, imipenem, ceftazidime and piperacillin/tazobactam. Based on a surveillance study conducted in Mainland China.1
AECOPD, acute exacerbation of chronic obstructive pulmonary disease; RTI, respiratory tract infection.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.